PORTON PHARMA SOLU revenue for the last year amounted to 3.67 B CNY, the most of which — 2.87 B CNY — came from its highest performing source at the moment, Late Clinical and Commercialization, the year earlier bringing 6.28 B CNY. The greatest contribution to the revenue figure was made by Overseas — last year it brought PORTON PHARMA SOLU 2.81 B CNY, and the year before that — 6.32 B CNY.